Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Spectrum Pharmaceuticals has earned a respected four-star ranking.
With that in mind, let's take a closer look at Spectrum and see what CAPS investors are saying about the stock right now.
Henderson, Nev. (1987)
Chairman/CEO Dr. Rajesh Shrotriya (since 2002)
Return on Equity (average, past 3 years)
Cash / Debt
$146.6 million / $75.0 million
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 98% of the 454 members who have rated Spectrum believe the stock will outperform the S&P 500 going forward.
The company has a strong pipeline of drugs, keeps getting approvals from the FDA, and has been building strong networks with physicians (prevents generics from taking back that much market share). Also, it has been said that Spectrum has only tapped roughly 50% of the possible physicians to date.
If you want market-topping returns, you need to put together the best portfolio you can. Of course, despite its four-star rating, Spectrum may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Spectrum Pharma Is Poised to Outperform originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.